Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06687234 (Dekavil) as Add-on to Infliximab in Active Ulcerative Colitis
NCT03269695Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2017
- Primary completion
- Jan 2021
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing PF-06687234 + Infliximab with Placebo + Infliximab (2 arms). Primary endpoints: Percentage of Participants in Modified Clinical Remission (Traditional Endoscopic Subscore <=1) at 12 weeks, Percentage of Participants in Modified Clinical Remission (Traditional Mayo Endoscopic Subscore <=1, Treatment Failure Approach) at 12 weeks and 2 more. Started Dec 2017; status: terminated.
02
Drugs
f8il10
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03269695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269695.